News | October 01, 2009

Positive Outcomes Reported With Supralimus Sirolimus-Eluting Stent With Biodegradable Polymer

Supralimus Sirolimus-Eluting Stent

October 1, 2009 – The six-month clinical outcome of Sahajanand Medical Technologies Supralimus Sirolimus-Eluting Stent with a bioabsorbable polymer was highlighted by the company at TCT 2009. The results were released at EuroPCR 2009 earlier this year and demonstrated excellent results in high risk patients with complex coronary lesions, including high procedural success rate (greater than 97 percent), and sustained safety.

Dr. Ricardo A. Costa, of the Cardiovascular Research Center, Brazil, offered preliminary clinical results at six months from the Multicenter E-Series Registry. He said the stent demonstrated clinical effectiveness of Supralimus in preventing revascularization, with only 2 percent target vessel revascularization (TVR) rate. There were no thrombosis events and no TVR/TLR in the Supralimus treated patient’s in-hospital. The stent thrombosis rate (definite/probable, ARC) up to six months was less than 1 percent.

Out-of Hospital adverse events (N=718) included 2 percent cardiac death, 0.5 percent myocardial infarction (MI) and 4.5 percent of major adverse cardiac event (MACE). Thus the preliminary data with the Supralimus Sirolimus-Eluting Stent has shown promising results, Dr. Costa said.

The study was conducted by Dr. Alexandre Abizaid, Dr. Costa and others from Jan 2007, which involved 1,181 patients with 1,260 lesions and prospectively enrolled in 50 cities of Brazil, Venezuela and India. The included patients were real world scenario with routine or emergency PCI. Mean age of patients was 64 years and risk factors included 79 percent hypertension, 38 percent diabetes, 31 percent smoker, 23 percent with previous MI, 64 percent with dyslipidemia, 34 percent with previous PCI and 46 percent with family history of CAD.

For more information: www.smtpl.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
New Study Focuses on Protein Responsible For Increased Heart Disease Risk
News | Cardiac Diagnostics| August 03, 2017
August 3, 2017 — A study to reduce the strongest inherited...
Overlay Init